BruceJosephRothMD

Oncology • Saint Louis, MO

Genitourinary Oncology, Hematologic Oncology

Professor of Medicine Washington University in St. Louis

Join to view full profile

Dr. Roth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Roth's full profile

Already have an account?

Office
5225 Mid America Plz
# Dv
Saint Louis, MO 63129
Phone+1 800-647-2098

Fax+1 314-362-3192

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1986
Indiana University School of MedicineResidency, Internal Medicine, 1980 - 1983
Indiana University School of MedicineInternship, Internal Medicine, 1980 - 1981
Saint Louis University School of MedicineClass of 1980

Certifications & Licensure

MO State Medical License 2010 - 2025
TN State Medical License 1999 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Fellow (FASCO) American Society of Clinical Oncologists, 2010
Join now to see all

Clinical Trials

Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Start of enrollment: 1997 Jul 15
Completed
Phase 2
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Start of enrollment: 1998 Dec 03
Completed
Phase 3
Combination Chemotherapy in Treating Patients With Bladder Cancer Start of enrollment: 1999 Apr 02
Completed
Phase 3
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2004 Jan 01
Terminated
Phase 1, Phase 2
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies Start of enrollment: 2013 May 07
Completed
Phase 1
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Michael J Morris, Glenn Heller, David W Hillman, Olivia Bobek, Charles Ryan
Journal of Clinical Oncology. 2023-06-20
20 citations
Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).
Neeraj Agarwal, Catherine M Tangen, Maha H A Hussain, Shilpa Gupta, Melissa Plets
Journal of Clinical Oncology. 2022-10-01
6 citations
Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemoth...
Benjamin W Fischer-Valuck, Sagar A Patel, Randall J Brenneman, John Christodouleas, Paul Sargos
European Urology Oncology. 2022-04-01

Press Mentions

Collaboration Between Rheumatologists, Primary Care Reduces Delay in Axial SpA DiagnosisAugust 4th, 2021
VA Pathologist Created Scoring System That Predicts Aggressiveness of Prostate CancerNovember 5th, 2020
New Drug May Boost Survival for Advanced Prostate Cancer Patients: Study - US NewsJune 2nd, 2014
Join now to see all

Committees

Member, Castration-resistant Prostate Cancer Guidelines Panel, AUA 2015 - 2018
Chairman, Oncology Drug Advisory Committee of the FDA 2014 - 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Fellow